Zacks Investment Research downgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a buy rating to a hold rating in a research note issued to investors on Monday, August 6th.
According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “
Several other equities research analysts have also issued reports on the stock. Cowen restated a buy rating and set a $95.00 price target on shares of Esperion Therapeutics in a research note on Monday, August 6th. Chardan Capital upgraded shares of Esperion Therapeutics to a hold rating and set a $32.50 price target for the company in a research note on Friday, July 20th. BidaskClub downgraded shares of Esperion Therapeutics from a buy rating to a hold rating in a report on Thursday, July 12th. Northland Securities downgraded shares of Esperion Therapeutics from an outperform rating to a market perform rating in a report on Wednesday, July 11th. Finally, ValuEngine raised shares of Esperion Therapeutics from a hold rating to a buy rating in a report on Wednesday, July 4th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Esperion Therapeutics has a consensus rating of Buy and an average price target of $81.81.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.70) by ($0.01). During the same quarter in the previous year, the firm posted ($1.92) EPS. analysts expect that Esperion Therapeutics will post -6.28 earnings per share for the current year.
In other news, major shareholder Target N. V. Biotech purchased 60,000 shares of the business’s stock in a transaction on Tuesday, June 5th. The stock was purchased at an average cost of $38.47 per share, with a total value of $2,308,200.00. Following the acquisition, the insider now directly owns 3,012,964 shares in the company, valued at $115,908,725.08. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Target N. V. Biotech purchased 50,000 shares of the business’s stock in a transaction on Friday, June 29th. The stock was purchased at an average cost of $39.48 per share, with a total value of $1,974,000.00. Following the completion of the acquisition, the insider now owns 3,182,964 shares in the company, valued at $125,663,418.72. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 330,000 shares of company stock valued at $13,259,300. Insiders own 32.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of ESPR. Two Sigma Advisers LP raised its position in shares of Esperion Therapeutics by 62.2% during the 4th quarter. Two Sigma Advisers LP now owns 24,000 shares of the biopharmaceutical company’s stock valued at $1,580,000 after buying an additional 9,200 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in Esperion Therapeutics in the 4th quarter worth $496,000. SG Americas Securities LLC raised its position in Esperion Therapeutics by 2,909.4% in the 1st quarter. SG Americas Securities LLC now owns 90,973 shares of the biopharmaceutical company’s stock worth $6,580,000 after purchasing an additional 87,950 shares during the period. American Century Companies Inc. raised its position in Esperion Therapeutics by 18.2% in the 1st quarter. American Century Companies Inc. now owns 28,812 shares of the biopharmaceutical company’s stock worth $2,084,000 after purchasing an additional 4,445 shares during the period. Finally, Virginia Retirement Systems ET AL purchased a new position in Esperion Therapeutics in the 1st quarter worth $347,000.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
See Also: Understanding Stock Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.